Search

Your search keyword '"Rivas, Candy"' showing total 13 results
Start Over Author "Rivas, Candy" Publication Year Range Last 3 years
13 results on '"Rivas, Candy"'

1. Supplementary Figure 4 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure 1 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figure Legend from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table 1 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Figure 3 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

6. Data from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 5 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Table 2 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 2 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Author

Miyajima, Naoto, primary, Tsutsumi, Shinji, primary, Sourbier, Carole, primary, Beebe, Kristin, primary, Mollapour, Mehdi, primary, Rivas, Candy, primary, Yoshida, Soichiro, primary, Trepel, Jane B., primary, Huang, Ying, primary, Tatokoro, Manabu, primary, Shinohara, Nobuo, primary, Nonomura, Katsuya, primary, and Neckers, Len, primary

Published
2023
Full Text
View/download PDF

10. β‐Arrestin‐biased proteinase‐activated receptor‐2 antagonist C781 limits allergen‐induced airway hyperresponsiveness and inflammation

Author

Schiff, Hillary V., primary, Rivas, Candy M., additional, Pederson, William P., additional, Sandoval, Estevan, additional, Gillman, Samuel, additional, Prisco, Joy, additional, Kume, Moeno, additional, Dussor, Gregory, additional, Vagner, Josef, additional, Ledford, Julie G., additional, Price, Theodore J., additional, DeFea, Kathryn A., additional, and Boitano, Scott, additional

Published
2022
Full Text
View/download PDF

12. Proteinase‐activated receptor‐2 antagonist C391 inhibits Alternaria‐induced airway epithelial signalling and asthma indicators in acute exposure mouse models

Author

Rivas, Candy M., primary, Yee, Michael C., additional, Addison, Kenneth J., additional, Lovett, Marissa, additional, Pal, Kasturi, additional, Ledford, Julie G., additional, Dussor, Gregory, additional, Price, Theodore J., additional, Vagner, Josef, additional, DeFea, Kathryn A., additional, and Boitano, Scott, additional

Published
2022
Full Text
View/download PDF

13. β‐Arrestin‐biased proteinase‐activated receptor‐2 antagonist C781 limits allergen‐induced airway hyperresponsiveness and inflammation.

Author

Schiff, Hillary V., Rivas, Candy M., Pederson, William P., Sandoval, Estevan, Gillman, Samuel, Prisco, Joy, Kume, Moeno, Dussor, Gregory, Vagner, Josef, Ledford, Julie G., Price, Theodore J., DeFea, Kathryn A., and Boitano, Scott

Subjects
*ARRESTINS, *ALTERNARIA alternata, *G protein coupled receptors, *INFLAMMATION, *BIOTHERAPY, *EPITHELIAL cells, *LABORATORY mice
Abstract

Background and Purpose: Asthma is a heterogenous disease strongly associated with inflammation that has many different causes and triggers. Current asthma treatments target symptoms such as bronchoconstriction and airway inflammation. Despite recent advances in biological therapies, there remains a need for new classes of therapeutic agents with novel, upstream targets. The proteinase‐activated receptor‐2 (PAR2) has long been implicated in allergic airway inflammation and asthma and it remains an intriguing target for novel therapies. Here, we describe the actions of C781, a newly developed low MW PAR2 biased antagonist, in vitro and in vivo in the context of acute allergen exposure. Experimental Approach: A human bronchial epithelial cell line expressing PAR2 (16HBE14o‐ cells) was used to evaluate the modulation in vitro, by C781, of physiological responses to PAR2 activation and downstream β‐arrestin/MAPK and Gq/Ca2+ signalling. Acute Alternaria alternata sensitized and challenged mice were used to evaluate C781 as a prophylactically administered modulator of airway hyperresponsiveness, inflammation and mucus overproduction in vivo. Key Results: C781 reduced in vitro physiological signalling in response to ligand and proteinase activation. C781 effectively antagonized β‐arrestin/MAPK signalling without significant effect on Gq/Ca2+ signalling in vitro. Given prophylactically, C781 modulated airway hyperresponsiveness, airway inflammation and mucus overproduction of the small airways in an acute allergen‐challenged mouse model. Conclusion and Implications: Our work demonstrates the first biased PAR2 antagonist for β‐arrestin/MAPK signalling. C781 is efficacious as a prophylactic treatment for allergen‐induced airway hyperresponsiveness and inflammation in mice. It exemplifies a key pharmacophore for PAR2 that can be optimized for clinical development. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results